Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Surface Oncology stock in Canada | $7.69

Own Surface Oncology shares in just a few minutes.

Surface Oncology, Inc
NASDAQ: SURF - USD
BIOTECHNOLOGY
$6.01
-$0.06 (-0.99%)

Surface Oncology is a biotechnology business based in the US. Surface Oncology stocks (SURF.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.12 – a decrease of 12.91% over the previous week. Surface Oncology employs 51 staff and has a trailing 12-month revenue of around $89.2 million.

How to buy Surface Oncology stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SURF in this case.
  5. Research Surface Oncology stocks. The platform should provide the latest information available.
  6. Buy your Surface Oncology stocks. It's that simple.

How has Coronavirus impacted Surface Oncology's stock price?

Since the stock market crash in March caused by coronavirus, Surface Oncology's stock price has had significant positive movement.

Its last market close was $7.69, which is 49.93% up on its pre-crash value of $3.85 and 457.25% up on the lowest point reached during the March crash when the stocks fell as low as $1.38.

If you had bought $1,000 worth of Surface Oncology stocks at the start of February 2020, those stocks would have been worth $493.72 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,418.27.

Surface Oncology stock price

Use our graph to track the performance of SURF stocks over time.

Surface Oncology stocks at a glance

Information last updated 2021-07-28.
Latest market close$7.69
52-week range$5.15 - $14.4
50-day moving average $7.026
200-day moving average $8.5175
Wall St. target price$16.4
PE ratio 11.5261
Dividend yield N/A (0%)
Earnings per share (TTM) $0.529

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Surface Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Surface Oncology price performance over time

Historical closes compared with the last close of $7.69

1 month (2021-07-01) 4.20%
3 months (2021-04-30) 5.20%

Is Surface Oncology under- or over-valued?

Valuing Surface Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surface Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Surface Oncology's P/E ratio

Surface Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Surface Oncology stocks trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

Surface Oncology's EBITDA

Surface Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.3 million.

The EBITDA is a measure of a Surface Oncology's overall financial performance and is widely used to measure a its profitability.

Surface Oncology financials

Revenue TTM USD$89.2 million
Operating margin TTM 28.82%
Gross profit TTM USD$86.3 million
Return on assets TTM 9.29%
Return on equity TTM 17.63%
Profit margin 23.78%
Book value $3.663
Market capitalisation USD$264.8 million

TTM: trailing 12 months

How to short and sell Surface Oncology stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SURF.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 4.8 million Surface Oncology stocks held short by investors – that's known as Surface Oncology's "short interest". This figure is 12.6% up from 4.3 million last month.

There are a few different ways that this level of interest in shorting Surface Oncology stocks can be evaluated.

Surface Oncology's "short interest ratio" (SIR)

Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology stocks currently shorted divided by the average quantity of Surface Oncology stocks traded daily (recently around 1.1 million). Surface Oncology's SIR currently stands at 4.54. In other words for every 100,000 Surface Oncology stocks traded daily on the market, roughly 4540 stocks are currently held short.

However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology stocks, or, against the total number of tradable Surface Oncology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.11% of the outstanding stocks (for every 100,000 Surface Oncology stocks in existence, roughly 110 stocks are currently held short) or 0.1469% of the tradable stocks (for every 100,000 tradable Surface Oncology stocks, roughly 147 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Surface Oncology.

Find out more about how you can short Surface Oncology stock.

Surface Oncology stock dividends

We're not expecting Surface Oncology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Surface Oncology stock price volatility

Over the last 12 months, Surface Oncology's stocks have ranged in value from as little as $5.15 up to $14.4. A popular way to gauge a stock's volatility is its "beta".

SURF.US volatility(beta: 1.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.8426. This would suggest that Surface Oncology's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Surface Oncology overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stocks similar to Surface Oncology

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site